A detailed history of Caxton Associates LLP transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 16,450 shares of HRMY stock, worth $559,793. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,450
Holding current value
$559,793
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 17, 2025

BUY
$26.76 - $38.05 $440,202 - $625,922
16,450 New
16,450 $453,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.01B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Caxton Associates LLP Portfolio

Follow Caxton Associates LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LLP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LLP with notifications on news.